RESEARCH ARTICLE

J Bras Patol Med Lab. 2024; 60(1): 08-15.

Advancement in Molecular Diagnostics. Impact on Personalized Medicine

10.1900/JBPML.2024.60.01.002

Riemelt Abel[1], Potente Kruger[2]

[1] Department of Urology, University of Leipzig, Liebigstraße 20, 04103, Leipzig, Germany
[2] Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Härtelstraße 16–18, 04107, Leipzig, Germany

Abstract

With the emergence of personalised medicine, healthcare has undergone a radical change as treatment plans are now based on a patient's unique genetics, lifestyle, and environment. This paradigm change has significant ramifications for many areas of healthcare, including the creation of tailored treatments and cutting-edge diagnostics, as well as patient empowerment over healthcare choices. Through the use of genomics, personalised medicine can identify genetic markers linked to certain diseases. Due to this knowledge, healthcare professionals may now prescribe less harmful and more successful therapies, especially in cancer therapy. Furthermore, improved medication responses and more precise diagnoses are made possible by the research of pharmacogenomics and sophisticated diagnostic instruments. Treatment is not the only effect; preventative measures based on a person's genetic predispositions also have an influence. Knowing their health risks gives patients the power to take charge of their treatment, actively participate in conversations with medical professionals, and make well-informed decisions. Personalised treatment has a significant potential for long-term cost-effectiveness, notwithstanding possible upfront expenses. It can optimise healthcare resource utilisation by lowering adverse responses, hospital readmissions, and ineffective therapies. Personalised medicine will continue to impact medication development and research, resulting in more focused and effective methods. Technology and stakeholder collaboration innovations could further mould healthcare into a more customised, efficient, and patient-focused approach. The summary succinctly captures how personalised medicine is revolutionising healthcare and its broad implications in the future.

Keywords: Advancement (AA), Molecular Diagnostics (MD), Personalized Medicine (PM),

Introduction

As we all know and accept, science and technology have become very important and useful in our daily lives. The achievements of science and technology have prevailed in each aspect of life such as medicine, health, industry, communication, enhancing and improving lifestyles, and others. In this study, we are going to overview the main advancements in molecular diagnostics that have a perpetual impact on personalized medicine. The term "molecular Diagnostics " can be explained in these words " the set of techniques which are useful for analyzing different biological markers related to genome and the other proteome[1]. It is also related to the study of genes and how they express themselves in cells from time to time that causes the cell to perform its function effectively. ". The discipline of molecular diagnostics has been merged with many other disciplines, leading to a better understanding and development of genomics [2].

It now has a main concentration and focuses on the pathogenic factors that take place at the genomic level in the cell. There is a variety of techniques in molecular diagnostics that have played a role in understanding structural and functional genomics[3]. It has provided us with a better understanding and exploration of those genes that are related to diseases in the body. These technologies include mutation scanning, DNA chip technology, hybridization, PCR, two-hybrid technology, sequence-based technology, and next-generation sequencing [4]. A marvelous technology named microarray chip technology has enabled the study of parallel analysis of thousands of genes at the same time. Not only has this, but the information on the sequence of the genome played a very important role in the discovery of single nucleotide polymorphism, which is abbreviated as SNPs. Another important technique is immunoassay biotechnology, which enables the encoding of genes of antibodies in a very short period[5]. As we all know, the whole health system is dependent upon better Diagnostics. There are many approaches to studying genetics for disease treatment, such as genetic tests for cancer treatment, genetics of microorganisms to get antibiotics, genetics study for disease prevention, genetics study for health management, and others. If we talk about the history of molecular Diagnostics, we will know that this field of biology grew in the twentieth century. One of the most important Diagnostics is colorectal cancer, abbreviated as CRC [6]. It has become the most widespread cancer across the world; every third man and every second woman is affected by it in the whole world[7].

There are a variety of techniques used for the diagnosis of this cancer depending upon pathological characteristics present in that specific tumor. A few surgeries are also suggested, such as laparoscopic surgery, open surgery tumour resection, and adjuvant radiotherapy. A few traditional screening methods are used to diagnose this cancer, such as faecal occult blood tests and faecal immunochemical tests. But nowadays, few Biomarkers are used for early diagnosis, such as carcinoembryonic antigen and insulin-like growth factors[8]. To help with disease diagnosis, aetiology, prognosis, and therapy, molecular pathology focuses on the analysis and interpretation of molecular and genetic alterations in tissues and cells. Molecular pathologists analyse genetic mutations, gene expression patterns, epigenetic changes, and protein abnormalities to comprehend the fundamental processes guiding the onset and course of disease. Because of this, molecular pathology has a wider application and breadth than molecular diagnostics. Molecular pathologists collaborate closely with clinicians, oncologists, and other healthcare professionals to link particular molecular abnormalities with histopathological findings, biomarkers, clinical data, and patient outcomes. This contrasts with molecular

First submission on 16/02/2023; accepted for publication on 05/01/2024; published on 15/01/2024

diagnostics, which primarily focus on identifying specific biomarkers. By offering a strong basis for precise diagnosis, prognosis, and treatment response prediction, this all-encompassing engagement seeks to enhance patient outcomes greatly. The mutation in cancerous cells can be detected by using circulating free DNA.

These circulating DNA can shed continuously from normal and tumour cells directly into the bloodstream; thus, this help reflects the entire genome of that tumour. One of the most important circulating DNA is methylated Septin, which can be used for early diagnosis of this cancer. As the whole world is facing increasing cases of hepatitis B throughout the world. Although effective vaccines are available, the cost of these vaccines is very high[9]. However, molecular Diagnostics has also played an important role in early detection of this virus. The main problem in diagnosing hepatitis is the distinction of the hepatitis B virus from other viruses related to hepatitis. In diagnosing the hepatitis B virus, we have to detect hepatitis B antigens and the presence or absence of viral components such as nucleic acid in blood or other hepatic sites[10].

In the case of molecular diagnostics of the hepatitis B virus, HBV surface antigens are detected by molecular diagnostics. An important molecular method is the thermal cycling technique, which is used for the amplification of the DNA of the HBV virus. Nucleic acid sequence-based amplification is also used, abbreviated as NASBA; transcription-mediated amplification, abbreviated as TMA; and rolling circle amplification, abbreviated as RCA, are mostly used. Every technique has its advantages and disadvantages as well[11]. There is no doubt that polymerase chain reaction is an effective way to assess and analyze the number of liver cells affected by the hepatitis virus, but this technique also needs invasive procedures. The other technique is ligase chain reaction, in which two sequences of nucleic acids are bound together by ligase enzyme, and then polymerase chain reactions proceed further. The other important technique is loop-mediated isothermal amplification, abbreviated as LAMP, which can be used to detect viral RNA[12].

Different viruses work in the body by reverse transcription, which converts viral RNA into viral DNA. This DNA surpasses host DNA and thus causes diseases. If early detection of viral RNA can be made possible, then all of these diseases can be detected and treated at a very early stage of the disease. All of these molecular diagnostics tell us about the achievements of science and technology in our medical field. We came across different methods and techniques for early disease detection, contrasting them with previous traditional methods for diagnosis. There is no doubt that this is evidence of the importance of science and technology in our daily life, but there are also some drawbacks related to molecular Diagnostics. First and foremost is the high cost of molecular Diagnostics that obstructs the proper implementation of it in every healthcare centre. Secondly, it needs highly skilled professionals for accurate analysis and detection of disease at an early stage. However, molecular Diagnostics will have a bright future if these hurdles are solved in the future[13].

Research Objective

The main objective of this study is to understand the advancements in Molecular Diagnostics which have enabled us to detect different types of diseases early by using the genome. This study has also effectively explained the advantages and disadvantages of different techniques used in Molecular Diagnostics. The research determines Advancement in Molecular Diagnostics and its impact on Personalized Medicine. The research is divided into five sections. The first portion represents the introduction and the objective of the research.

The second portion represents the literature review; the third describes the research study methods. The fourth portion describes results and descriptions related to the Advancement in Molecular Diagnostics and its impact on Personalized Medicine. The last section summarizes the overall research study and presents some recommendations for future research related to molecular diagnostics and personalized medicine.

Literature Review

Recent studies in the field of molecular technologies have led to advancements in diagnostic techniques in which multiple disciplines come together to study events occurring at the pathogenic level. Molecular diagnostics provide physicians with critical information to explore disease-related genes and their effects on changes occurring in a patient's DNA and chromosomes[12]. Researchers claim that based on genetic tests of different individuals, the medical practice can be customized, and precision or personalized medicine can be produced. This field of medicine is gaining interest because of advancements in molecular diagnostics techniques and can help develop targeted drugs for patients[14].

Studies based on experiments have revealed different productive impacts of molecular diagnostics on producing personalized medicines. For example, recently, researchers supported the idea of applying molecular studies to create fertility medicines by assessing the data from different patients in fertility clinics. This data can be used to explore patterns of genes and individual profiles of patients to develop improved personalized medicines for treating infertility.[15]. Moreover, further advancements in the field of personalized medicine have been made by the whole exome sequencing (WES) technique of molecular diagnostics since WES covers almost 3% of the whole protein-coding genome and can act as a bioinformatic source in big data analytics as well[16].

Other medical conditions like sepsis, which occurs by bacterial infections, can also be diagnosed using genomic studies to develop personalized medicines. Modern molecular diagnostic techniques and instruments like SeptiCyte are currently used to provide a highly efficient diagnosis of sepsis[17]. Similarly, studies have shown an effective development of personalized medicine for melanoma treatment by using advanced MEK inhibitor and BRAF inhibitor therapy methods. Combining these treatments with immunotherapy can make more promising diagnostic outcomes possible[18]. Also, the treatment of cancer has been made possible by the implementation of precision medicine through the usage of molecular-based profiling technologies. This method has been known to augment prognostication and the required outcome of a personalized clinical analysis[19].

Similarly, researchers interpret that breast cancer diagnosis can be made more effectively by performing tests on mRNA instead of DNA because DNA variants can be difficult to interpret in this certain case. Also, RNA testing is already a practised technique in assessing recurring risk while performing chemotherapy sessions[20]. Besides, cancer treatments are also being made possible by developing personalized medicines with targeted nano theranostics involving the

study of drug delivery of nano-drug carriers at the genomic level[21]. Studies have shared the progressive outcomes of diagnostic information in personalized healthcare by actions of next-generation molecular sequencing techniques and brought out a comprehensive idea to enable the delivery of this skill into healthcare systems[22].

Another advancement has occurred in colourimetric detection methods of analytes as it is of great concern to have high sensitivity in this regard to come up with personalized medicines finally. For this purpose, researchers have proposed the implication of plasmonic nano-sensors to boost sensitivity[23]. Other than these, diabetes treatment can also be boosted by involving molecular diagnostic techniques, especially for type 2 diabetes, by developing personalized medicines based on every individual's genome testing[24].

Besides, in recent years, data scientists have also been involved in developing personalized or stratified medicine by combining data derived from molecular diagnostic techniques and patient features, including biomarkers of a molecular or behavioral nature[25]. Researchers have even made their way through advanced molecular and genomic methods like the use of CRISPR-Cas12a proteins that can slice double-stranded DNA in a sequence-precise way and they can tempt vigorous trans-cleavage of nonspecific single-stranded DNA. Researchers use this remark to develop a fast and precise examination to notice carcinoma-related HPV kinds 16 and 18 from scientific samples[26].

Tumors can have dissimilar fundamental hereditary causes and may show different proteins in one patient and distinct in another. This characteristic erraticism of cancer advances itself to the rising field of personalized and precision medicine. Many efforts are being made to get personalized medicine data in command to describe molecular changes between growths[27]. Studies showcase that knowledge of personalized medicine eases prior disease uncovering using heightened use of present biomarkers and finding early genomic and epigenomic happenings in disease development, especially carcinogenesis. This method mainly focuses on anticipatory medicine and motivates taking practical actions[28]. Furthermore, Metabolomics, which is the profiling of metabolites in biological matrices, is an important implement for the discovery of biomarkers and personalized medicine and has the possibility to explain the final invention of genomic procedures[29].

Parkinson's disease has also been sorted with the help of personalized medicine by studying the patient's genome using molecular diagnostic techniques and considering the specific phenotype and clinical evidence of the patient's profile[30]. Researchers have made discoveries in the documentation of genetic variations before the insertion of a medicine. This method requires top-notch practices to get hold of the intricacy of the molecules, which can bring an awareness of the compounds at their respective molecular levels [31, 32].

To benefit from this, the field of bioinformatics plays an important role in disclosing the mechanism of molecular mutation. It thereby can design a drug for a specific individual quickly and reasonably. Versatile computer-related methods, for instance, molecular dynamics simulation, have proved to be a productive approach to learning personalized medicine formation[33].

Recent research in stem cells at the molecular level has provided insight to clarify their part in the degeneration of tissue and pathogenesis and in understanding the high-end tools for developing and producing personalized recreating medicine guidelines [34]. In the intervening time, the evolving area of omics technologies ensures that transcribing genomics information based on structure can help elaborate molecular signatures of patients. Finally, molecular diagnosis has also made its mark in researching the pathway of neuroscience to predetermine the stages of brain cells and their functioning[35].

Methods

The research determines Advancement in Molecular Diagnostics and its impact on Personalized Medicine. The research based on the primary data analysis to determine the research used specific research questions related to molecular diagnostics and personalized medicine. The research measured by the smart PLS Algorithm model included descriptive statistics and correlation coefficients.

Discovery of Molecular Diagnostics: History and Developments

The era of discoveries in molecular biology started in the late 20th century. The term "molecular diagnostics" was specifically coined in the 1980s by different emerging companies. The discovery of new genes and their new sequencing methodologies began in the 1990s, which gave a final push for molecular diagnostics to appear as a field. In 1949, Pauling and his research mates called this field a molecular disease when they discovered that replacing a single amino acid can lead to sickle cell anaemia. That is exactly when the foundation of molecular diagnostics was laid, and with developing times, molecular diagnostic methods have faced severe advancements like finding gene mutations and prior identification of inherited diseases.

Molecular Diagnostic Methods of Characterization

Exact identification of disease-causing agents like microbes, alterations in protein levels, and genetic sequencing are very important in laying out specific and sensitive diagnostic tools for patients. The early discovery of PCR has been beneficial in that course, but methods like microarrays, peptide sequencers, etc., give much better results in less time. Out of these advanced methods, a few are briefed below.

Implementation of Molecular Diagnostics on Personalized Medicines

Personalized medicine is the field in which patients are diagnosed based on their disease, prognosis, and response to particular genetic tests. Modern advancements are using molecular diagnostics to study pathogenic events at the genomic level and create personalised medicines based on an individual's profile. Diverse advancements are being made in which molecular diagnostics are used for designing personal medicines.

Variety of Sequencing Methods

In Single Cell Sequencing molecular diagnostic method, the individual cell is analyzed separately, giving information about the heterogenic nature of genetics in tissues. This particular method is important for scheming personalized medicine for cancer diagnostics and getting the details about disease at the cellular level.

The next-generation sequencing method of molecular diagnostics is used to produce personalized medicine by analyzing genetic variations from person to person. This method is known to have

increased precision, cheaper costs, and a faster result rate.

Incorporation of Omics and Non-Genomic Data

Different data-sourcing techniques are used and compiled to analyse an individual's molecular profile. These data sources can be from different genomic studies like proteomics, transcriptomics, metabolomics, etc. By analyzing these data sets together, an individual's disease can be interpreted more efficiently, and treatment strategies can be applied more precisely.

Other than DNA sequencing, evaluation of non-genetic modifications like DNA methylation and modification of histone proteins can help analyse the gene expression and study disease mechanisms more accurately so that every individual can get personalized medical care.

Simultaneous Assessment Using Artificial Intelligence

In this strategy, implementation of molecular diagnostics and therapeutic strategies is made possible, simultaneously. This allows physicians to develop effective personalized medicines according to patient's requirements. Machine learning and artificial intelligence is the emerging field of interest these days.

Implementing these AI tools in analyzing a large amount of molecular data allows the field of precision medicine to develop more progressive types of treatments that have higher efficiency rates. Point-of-care testing can be done by introducing molecular diagnostic devices that provide fast and easy analysis of molecular and genetic markers.

Assays of Lipid-Containing Samples

This method is useful in studying circulating tumour DNA (ctDNA) to study genetic material present in body fluids, i.e., blood. It is a real-time test that gives information about tumor mutations without invasion, enabling it to track disease progression and response toward treatment.

Learning of Drug Response

One of the key aspects of the proper application of personalized medicine is the achievement of its proper response by an individual's body. For this, the study of an individual's genetic makeup and how it gets affected by medications needs to be done. Pharmacogenomics is the field that can help in this regard by helping optimize drug selection and the amount of positive treatment responses.

In this way, molecular diagnostic methods in other fields can give a high-end output on a patient's individuality and data about his genomics. Different analyses of genotypes and phenotypes of patients can allow the treatment of disease more efficiently and can help physicians to generate personalized medicines with which the competence level of treatment can be increased from patient to patient.

Smart PLS Algorithm Model



Figure 1

The above model represents that the smart PLS Algorithm model result shows that AMD and PM link with each other. According to the above analysis, AMD is the main independent variable.

It shows that 0.682, 0.192, 0.802, -0.445, 0.423, and 0.133 show that 68%, 19%, 80%, 44%, 42% and 13% significant levels between them. The PM describes that -0.680, 0.584, 0.135, 0.514 shows 64%, 58%, 13%, and 51% significant rates between them.

The paragraph suggests that AMD is the main independent variable, and it has varying levels of significant relationships with PM as indicated by the coefficients and associated percentages.Similarly, PM has coefficients and percentages indicating its relationships with AMD.

Descriptive statistic

Table 1

Name	No.	Mean	Median	Scale min	Scale max	Standard deviation	Excess kurtosis	Skewness	Cramér-von Mises p value
AMD1	0	1.510	1.000	1.000	3.000	0.610	-0.305	0.794	0.000
AMD2	1	1.510	1.000	1.000	3.000	0.610	-0.305	0.794	0.000
AMD3	2	1.367	1.000	1.000	3.000	0.560	0.721	1.270	0.000
AMD4	3	1.408	1.000	1.000	3.000	0.531	-0.509	0.803	0.000
AMD5	4	1.367	1.000	1.000	3.000	0.560	0.721	1.270	0.000
AMD6	5	1.592	2.000	1.000	3.000	0.569	-0.756	0.312	0.000
PM1	6	1.449	1.000	1.000	3.000	0.608	0.125	1.044	0.000
PM2	7	1.469	1.000	1.000	3.000	0.642	0.081	1.072	0.000
PM3	8	1.612	2.000	1.000	3.000	0.600	-0.615	0.426	0.000
PM4	9	1.469	1.000	1.000	3.000	0.575	-0.329	0.788	0.000
PM5	10	1.469	1.000	1.000	3.000	0.538	-0.915	0.530	0.000
PM6	11	1.714	2.000	1.000	3.000	0.728	-0.967	0.514	0.000
PM7	12	1.592	1.000	1.000	3.000	0.668	-0.544	0.713	0.000
PM8	13	1.694	2.000	1.000	3.000	0.613	-0.585	0.303	0.000
PM9	14	1.408	1.000	1.000	3.000	0.531	-0.509	0.803	0.000

The above results describe that descriptive statistical analysis results present that mean, median, minimum, and maximum values also explain the standard deviation rates of each independent and dependent variable. The mean values of AMD1, 2, 3, 4, 5, and 6 are 1.367, 1.408, 1.367, and 1.592, respectively. These all present a positive average value of mean. The standard deviation rates of each independent variable are 72%, 50%, 75%, and 30% deviate from the mean. The overall result shows that the minimum value is 1.000, the maximum value is 3.000, and the overall probability value is 0.000, which shows a 100% significant level between them. the PM is a dependent variable according to the result PM1,2,3,4,5,6,7,8 and 9.

These are all factors considered dependent variables. Results describe that mean values are 1.449, 1.469, 1.612, 1.714, 1.592, and 1.408. These are shows the positive average value of the mean. The standard deviation rates are 57%, 53%, 72%, 66%, 61%, and 53%, which deviate from mean values. The skewness values show the negative rates of each indicator.

Implementation of Microarrays and DNA Sequencing Strategies

This method involves crossing DNA with the targeted molecule to find out qualitative and quantitative characteristics of different genotype districts. Yeast and molds have been known to be identified by using microarray techniques on fungal rRNA. The microbial activity of *Bacillus anthracis* can be identified by using an oligonucleotide microarray. DNA sequencing has been proven a successful method for determining genetic mutations that allows the identification of nucleotide base order in DNA molecules. Chemical degradation and chain termination techniques are two commonly approved DNA sequencing methodologies. However, the chain-terminator method became a wide-ranging DNA sequencing technique due to its better competence and use of rarer poisonous substances and reduced quantities of radioactivity than the chemical degradation method.

Assessment of Proteinaceous Analyses

These analyses can include techniques involving western blotting and enzyme-immunosorbent assays. Western blotting techniques of molecular diagnostics provide information on the protein charge and size of the individual, which in turn helps in studying and detecting particular proteins. On the other hand, enzyme-linked immunosorbent assays use antibodies to find and give quantitative data on proteins by allowing the attachment of these antibodies to specific target sights. Information achieved from these assays can help design personalized medicines for individuals.

Analysis through PCR

It is a quantitative assay technique that can amplify DNA sequences and was first used by Higuchi. This method is simple and uses fluorescent probes to perceive and can provide real-time quantification of PCR products being made. The real-time fluorescence observation makes this technique convenient and can be further divided into three methods i.e., electrophoretic, enzymatic, and solid-phased methods.

Correlation coefficient

Table 2

	AMD 1	AMD 2	AMD 3	AMD 4	AMD 5	AMD 6	PM 1	PM 2	PM 3	PM 4	PM 5	PM 6	PM 7	PM 8	PM 9
AMD1	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
AMD2	0.068	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
AMD3	0.347	0.168	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
AMD4	-0.076	0.239	-0.161	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
AMD5	0.228	-0.071	0.220	-0.161	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
AMD6	0.071	-0.164	-0.106	-0.124	-0.106	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
PM1	-0.067	-0.232	-0.005	0.001	0.295	-0.060	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
PM2	-0.038	-0.351	-0.025	-0.322	-0.082	0.022	0.244	1.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
PM3	-0.240	0.039	0.059	0.176	-0.183	-0.344	0.086	-0.110	1.000	0.000	0.000	0.000	0.000	0.000	0.000
PM4	-0.043	0.015	0.225	0.041	0.035	-0.475	0.389	0.343	0.350	1.000	0.000	0.000	0.000	0.000	0.000
PM5	0.203	0.079	0.240	-0.313	-0.030	0.226	-0.394	0.130	-0.195	-0.250	1.000	0.000	0.000	0.000	0.000
PM6	-0.223	-0.039	-0.593	0.090	-0.143	0.162	0.059	0.330	-0.207	-0.167	-0.230	1.000	0.000	0.000	0.000
PM7	0.261	0.261	0.401	-0.048	0.237	-0.116	-0.152	-0.553	0.267	0.021	-0.035	-0.534	1.000	0.000	0.000
PM8	-0.019	0.199	0.268	0.070	0.030	-0.124	0.095	0.002	0.232	0.118	-0.121	0.078	0.293	1.000	0.000
PM9	0.239	0.050	0.113	-0.373	0.045	0.484	0.064	0.216	-0.208	-0.093	0.472	0.038	-0.106	0.008	1.000

The above result describe that correlation coefficient analysis result represent that negative and positive correlation between them its rates are 0.199, 0.113, -0.373, -0.124 respectively present negative link between independent and dependent variables.

Precision medicine, another name for personalised medicine, is the practice of customising medical care to each patient's unique needs. This method customises healthcare decisions based on an individual's lifestyle, environment, and genetic composition. Personalised medicine has a significant and wide-ranging influence on many different facets of healthcare.

1. Targeted medicines: due to personalised medicine, medicines specifically tailored to a patient's genetic profile may be developed. This strategy is especially useful in the treatment of cancer, as medications may be created to target genetic abnormalities that cause tumour development specifically. In contrast to conventional, one-size-fits-all methods, this may lead to less harmful and more successful therapies.

2. Genomic Medicine: Personalised medicine has benefited greatly from advances in genomics. The capacity to sequence a person's genome yields important details on their hereditary susceptibilities to certain diseases, possible reactions to medications, and risk factors. Healthcare professionals can use this information to help them make better treatment decisions.

3. Advances in Diagnosis: The field of personalised medicine has resulted in the creation of sophisticated diagnostic instruments capable of identifying certain genetic signatures or biomarkers linked to particular diseases. This facilitates quicker action and individualised treatment programmes by enabling earlier and more accurate diagnosis.

4. Pharmacogenomics: This field of study examines how a person's genetic composition affects how they react to medications. By prescribing drugs that are more likely to be successful and have fewer side effects, healthcare professionals can improve overall treatment results by better understanding a patient's genetic variants.

5. Preventive Medicine: Preventive measures are a part of personalised medicine, which goes beyond therapy. Healthcare practitioners can give tailored preventative treatments, lifestyle suggestions, and screening programmes to lower the chance of developing a disease by determining an individual's genetic predispositions to certain disorders.

6. Patient Empowerment: By allowing patients to participate in their own healthcare decisions, personalised medicine empowers patients. People may actively engage in conversations with their healthcare professionals, make educated decisions, and take proactive measures to preserve their health if they have access to knowledge about their genetic make-up and potential health concerns.

7. Healthcare Economics: Personalised medication may be more expensive initially, but it may prove more economical over time. Customising care for each patient lowers the risk of side effects, hospital readmissions, and unsuccessful therapies, which saves money on healthcare costs overall.

8. Research and medication Development: Personalised medicine has impacted the medication development process by highlighting a focused and customised approach. This has sped up the time it takes to create new drugs, identify fresh therapeutic targets, and move the focus of clinical trials towards more successful and efficient ones.

Conclusion

To sum up, personalised medicine is a new development in healthcare that replaces the conventional one-size-fits-all paradigm with a precise and customised strategy. From focused medicines and genetic medicine to enhanced diagnostics and preventative methods, the effect of personalised medicine is visible in many areas of healthcare. Healthcare professionals can optimise the efficacy of therapies while mitigating unfavorable consequences by using genetic information and customising treatment strategies for individual patients. In addition to improving treatment results, personalised medicine has given people more power to engage actively in their healthcare decisions. With the knowledge of their genetic predispositions at their disposal, patients may now take proactive measures to preserve their health and make educated decisions.

Furthermore, the potential for long-term cost reductions through more effective therapies, fewer unpleasant effects, and optimal use of hospital resources is making the economic implications of personalised medicine increasingly clear. Precision medication delivery and design are expected to undergo promising advancements in the field of molecular therapies. Due to developments in pharmacogenomics, it will be possible to identify medication reactions unique to each patient, preventing the use of potentially hazardous or inefficient therapies. It is anticipated that combination therapies, which include immunotherapies, targeted medicines, and conventional treatments, would become potent treatment plans with beneficial side effects. Furthermore, gene editing technologies provide new therapeutic opportunities by treating genetic diseases at the molecular level and potentially correcting genetic abnormalities. The overall research concluded that there is a direct and significant link between them. Lastly, the ability of molecular treatments to quickly address infectious disease epidemics has been proven by the efficacy of RNA vaccines against infections like COVID-19. Only a small portion of the enormous and varied terrain our field covers may be covered in this Special Issue. However, the topic covers a wide range, including myocardial infarction, fibroids, cancer, inflammatory diseases, and mechanosensing.

In conclusion, personalised medicine is revolutionising healthcare by replacing the one-size-fits-all paradigm with a more accurate and customised approach. The combination of genetic data, sophisticated diagnostics, and focused medicines might completely change the way we prevent, detect, and treat diseases. This Special Issue also explores the field of mindfulness-based therapies, which goes beyond conventional medical boundaries. The fascinating investigations into the relationship between mindfulness and molecular biomarkers provide new avenues for integrative methods to mental health management and general well-being promotion. The Special Issue of 16 papers showcases an impressive array of contributions that underscore the intricacy and diversity of molecular pathology, diagnostics, and therapies.

Personalised medicine concepts will likely continue to impact research and medication development, which might lead to even more specialized and effective healthcare methods in the future. The field of personalised medicine will continue to grow due to the continuous integration of big data analytics, technology advancements, and patient-provider collaboration. This will ultimately transform the healthcare landscape into more effective, individualized, and patient-centric.

Reference

[1] S. A. Waldman and A. Terzic, "Companion diagnostics at the intersection of personalized medicine and healthcare delivery," *Biomarkers in medicine,* vol. 9, no. 1, pp. 1-3, 2015.

[2] W. Ding, S. Lenhart, and H. Behncke, "Discrete time optimal harvesting of fish populations with age structure," *Letters in Biomathematics,* vol. 1, no. 2, pp. 193-207, 2014, doi: https://doi.org/10.30707/LiB1.2Ding.

[3] S.-W. Pang *et al.*, "Current update of laboratory molecular diagnostics advancement in management of colorectal cancer (CRC)," *Diagnostics,* vol. 10, no. 1, p. 9, 2019.

[4] L. Zhen, "Research on mathematical teaching innovation strategy and best practices based on deep learning algorithm," *Journal of Commercial Biotechnology,* vol. 27, no. 3, 2022, doi: https://doi.org/10.5912/jcb1284.

[5] P. Hays, *Advancing healthcare through personalized medicine*. Crc Press, 2017.

[6] A. Perec, "Desirability function analysis (DFA) in multiple responses optimization of abrasive water jet cutting process," *Reports in Mechanical Engineering,* vol. 3, no. 1, pp. 11-19, 2022.

[7] L. Bissonnette and M. G. Bergeron, "Next revolution in the molecular theranostics of infectious diseases: microfabricated systems for personalized medicine," *Expert review of molecular diagnostics,* vol. 6, no. 3, pp. 433-450, 2006.

[8] P. Sharma and S. Dwivedi, "Prospects of molecular biotechnology in diagnostics: step towards precision medicine," vol. 32, ed: Springer, 2017, pp. 121-123.

[9] E. D. Blair, "Molecular diagnostics and personalized medicine: value-assessed opportunities for multiple stakeholders," *Personalized Medicine,* vol. 7, no. 2, pp. 143-161, 2010.

[10] G. S. Ginsburg and J. J. McCarthy, "Personalized medicine: revolutionizing drug discovery and patient care," *TRENDS in Biotechnology,* vol. 19, no. 12, pp. 491-496, 2001.

[11] K.-H. Jung and K.-H. Lee, "Molecular imaging in the era of personalized medicine," *Journal of pathology and translational medicine,* vol. 49, no. 1, pp. 5-12, 2015.

[12] S. Dwivedi *et al.*, "Diseases and molecular diagnostics: a step closer to precision medicine," *Indian Journal of Clinical Biochemistry,* vol. 32, pp. 374-398, 2017.

[13] F. S. Ong *et al.*, "Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing," *Expert review of molecular diagnostics,* vol. 12, no. 6, pp. 593-602, 2012.

[14] J. A. B. Iriart, "Precision medicine/personalized medicine: a critical analysis of movements in the transformation of biomedicine in the early 21st century," *Cadernos de saúde publica,* vol. 35, 2019.

[15] L. H. Goetz and N. J. Schork, "Personalized medicine: motivation, challenges, and progress," *Fertility and sterility,* vol. 109, no. 6, pp. 952-963, 2018.

[16] P. Suwinski, C. Ong, M. H. Ling, Y. M. Poh, A. M. Khan, and H. S. Ong, "Advancing personalized medicine through the application of whole exome sequencing and big data analytics," *Frontiers in genetics,* vol. 10, p. 49, 2019.

[17] M. Sinha, J. Jupe, H. Mack, T. P. Coleman, S. M. Lawrence, and S. I. Fraley, "Emerging technologies for molecular diagnosis of sepsis," *Clinical microbiology reviews,* vol. 31, no. 2, pp. 10.1128/cmr. 00089-17, 2018.

[18] L. Cheng, A. Lopez-Beltran, F. Massari, G. T. MacLennan, and R. Montironi, "Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine," *Modern Pathology,* vol. 31, no. 1, pp. 24-38, 2018.

[19] E. R. Malone, M. Oliva, P. J. Sabatini, T. L. Stockley, and L. L. Siu, "Molecular profiling for precision cancer therapies," *Genome medicine,* vol. 12, no. 1, pp. 1-19, 2020.

[20] H. Čelešnik and U. Potočnik, "Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer," *Cancers,* vol. 15, no. 4, p. 1087, 2023.

[21] S. D. Jo, S. H. Ku, Y.-Y. Won, S. H. Kim, and I. C. Kwon, "Targeted nanotheranostics for future personalized medicine: recent progress in cancer therapy," *Theranostics,* vol. 6, no. 9, p. 1362, 2016.

[22] V. Wurcel *et al.*, "The value of diagnostic information in personalised healthcare: a comprehensive concept to facilitate bringing this technology into healthcare systems," *Public health genomics,* vol. 22, no. 1-2, pp. 8-15, 2019.

[23] L. Tang and J. Li, "Plasmon-based colorimetric nanosensors for ultrasensitive molecular diagnostics," *ACS sensors,* vol. 2, no. 7, pp. 857-875, 2017.

[24] M. I. McCarthy, "Painting a new picture of personalised medicine for diabetes," *Diabetologia,* vol. 60, no. 5, pp. 793-799, 2017.

[25] H. Fröhlich *et al.*, "From hype to reality: data science enabling personalized medicine," *BMC medicine,* vol. 16, no. 1, pp. 1-15, 2018.

[26] D. S. Chertow, "Next-generation diagnostics with CRISPR," *science,* vol. 360, no. 6387, pp. 381-382, 2018.
[27] P. Krzyszczyk *et al.*, "The growing role of precision and personalized medicine for cancer treatment," *Technology,* vol. 6, no. 03n04, pp. 79-100, 2018.
[28] S. Mathur and J. Sutton, "Personalized medicine could transform healthcare," *Biomedical reports,* vol. 7, no. 1, pp. 3-5, 2017.
[29] M. Jacob, A. L. Lopata, M. Dasouki, and A. M. Abdel Rahman, "Metabolomics toward personalized medicine," *Mass spectrometry reviews,* vol. 38, no. 3, pp. 221-238, 2019.
[30] N. Titova and K. R. Chaudhuri, "Personalized medicine in Parkinson's disease: time to be precise," *Movement Disorders,* vol. 32, no. 8, p. 1147, 2017.
[31] L. Zhao, "Global Path Planning of Mobile Robot for Agricultural Ground Robots," *Journal of Commercial Biotechnology,* vol. 27, no. 5, pp. 253-264, 2022, doi: https://doi.org/10.5912/jcb1100.
[32] J. Stefanović-Marinović, Ž. Vrcan, S. Troha, and M. Milovančević, "Optimization of two-speed planetary gearbox with brakes on single shafts," *Reports in Mechanical Engineering,* vol. 3, no. 1, pp. 94-107, 2022.
[33] P. Sneha and C. G. P. Doss, "Molecular dynamics: new frontier in personalized medicine," *Advances in protein chemistry and structural biology,* vol. 102, pp. 181-224, 2016.
[34] T. D. Comar, M. Hegazy, M. Henderson, and D. Hrozencik, "A comparison of the Boolean and continuous dynamics of three-gene regulatory networks," *Letters in Biomathematics,* vol. 1, no. 1, pp. 51-65, 2014, doi: https://doi.org/10.30707/LiB1.1Comar.
[35] W. Lattanzi *et al.*, "Basic and preclinical research for personalized medicine," *Journal of Personalized Medicine,* vol. 11, no. 5, p. 354, 2021.